vimarsana.com
Home
Live Updates
Black Diamond Therapeutics Presents Promising BDTX-1535 Clinical Data in Patients with Recurrent Glioblastoma at 2024 American Society of Clinical Oncology (ASCO) Annual Meeting : vimarsana.com
Black Diamond Therapeutics Presents Promising BDTX-1535 Clinical Data in Patients with Recurrent Glioblastoma at 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
Results from Phase 1 dose escalation trial of BDTX-1535 in GBM patients demonstrated a favorable safety and tolerability profile, and encouraging anti-tumor activity and duration of treatment ...
Related Keywords
United States ,
Cambridge ,
Cambridgeshire ,
United Kingdom ,
Black Diamond ,
Arizona ,
American ,
Nader Sanai ,
Patrick Wen ,
Mario Corso ,
Nasdaq ,
Ivy Brain Tumor Center ,
International Conference On Molecular ,
Globenewswire Inc ,
Exchange Commission ,
American Society Of Clinical Oncology ,
Diamond Therapeutics Inc ,
Dana Farber Cancer Institute ,
Company Masterkey ,
Diamond Therapeutics ,
Clinical Oncology ,
Farber Cancer ,
Generation Covalent ,
Recurrent Glioblastoma ,
Dose Escalation Results ,
Molecular Targets ,
Trigger Trial ,
Recurrent High Grade Glioma ,
Ivy Brain Tumor ,
Private Securities Litigation Reform Act ,
Annual Report ,
States Securities ,
Investor Relations ,
vimarsana.com © 2020. All Rights Reserved.